Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer

British Journal of Cancer

Volumn 106, Issue 4, 2012, Pages 638-645

  King, M T ^a,b   Viney, R ^b   Smith, D P ^c   Hossain, I ^b,d   Street, D ^b   Savage, E ^b   Fowler, S ^b   Berry, M P ^e   Stockler, M ^a,f,g   Cozzi, P ^h   Stricker, P ⁱ   Ward, J ^j   Armstrong, B K ^g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c CANCER RESEARCH DIVISION   (Australia)

^d QATAR UNIVERSITY   (Qatar)

^e MACQUARIE UNIVERSITY HOSPITAL   (Australia)

^f SYDNEY CANCER CENTRE   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

preferences; prostate cancer; quality of life; survival benefit; trade off; utility

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISCRETE CHOICE EXPERIMENT; DISEASE SEVERITY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEALTH SURVEY; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; URINE INCONTINENCE;

AGED; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; ERECTILE DYSFUNCTION; HUMANS; INTESTINAL DISEASES; MALE; MIDDLE AGED; PATIENT PREFERENCE; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; UROLOGIC DISEASES;

EID: 84862777714     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.552     Document Type: Article

References (44)

1. Barry MJ (2009) Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 360: 1351-1354
2. Bremner KE, Chong CAKY, Tomlinson G, Alibhai SMH, Krahn MD (2007) A Review and Meta-Analysis of Prostate Cancer Utilities. Med Decis Making 27: 288-298 (Pubitemid 46801746)
3. Bruner DW, Hanlon A, Mazzoni S, Raysor S, Konski A, Hanks G, Pollack A (2004) Predictors of preferences and utilities in men treated with 3DCRT for prostate cancer. Int J Radiat Oncol Biol Phys 58: 34-42 (Pubitemid 38010334)
4. Chapman GB, Elstein AS, Kuzel TM, Nadler RB, Sharifi R, Bennett CL (1999) A multi-attribute model of prostate cancer patient's preferences for health states. Qual Life Res 8: 171-180 (Pubitemid 29367287)
5. Chapman GB, Elstein AS, Kuzel TM, Sharifi R, Nadler RB, Andrews A, Bennett CL (1998) Prostate cancer patients' utilities for health states: How it looks depends on where you stand. Med Decis Making 18: 278-286 (Pubitemid 28307557)
6. Davison BJ, Parker PA, Goldenberg SL (2004) Patients' preferences for communicating a prostate cancer diagnosis and participating in medical decision-making. BJU Int 93: 47-51 (Pubitemid 38112962)
7. Duric V, Stockler MR (2001) A systematic review of studies assessing patients' preferences for adjuvant chemotherapy in early breast cancer: What makes it worthwhile? Lancet Oncol 2: 691-697 (Pubitemid 33085815)
8. Elstein AS, Chapman GB, Chmiel JS, Knight SJ, Chan C, Nadler RB, Kuzel TM, Siston AK, Bennett CL, Elstein AS, Chapman GB, Chmiel JS, Knight SJ, Chan C, Nadler RB, Kuzel TM, Siston AK, Bennett CL (2004) Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expect 7: 115-125 (Pubitemid 38661166)
9. Elstein AS, Chapman GB, Knight SJ, Elstein AS, Chapman GB, Knight SJ (2005) Patients' values and clinical substituted judgments: The case of localized prostate cancer. Health Psychol 24: S85-S92 (Pubitemid 41099130)
10. Gore J, Kwan L, Lee SP, Reiter RE, Litwin MS. (2009) Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localised prostate cancer. J Natl Cancer Inst 101: 888-892
11. Jenkins V, Fallowfield L, Edginton T, Payne H, Hamilton E (2005) Preferences of healthy men for two different endocrine treatment options offered for locally advanced prostate cancer. Curr Med Res Opin 21: 1329-1335 (Pubitemid 41368563)
12. Knight SJ, Siston AK, Chmiel JS, Slimack N, Elstein AS, Chapman GB, Nadler RB, Bennett CL (2004) Ethnic variation in localized prostate cancer: A pilot study of preferences, optimism, and quality of life among black and white veterans. Clin Prostate Cancer 3: 31-37 (Pubitemid 39006584)
13. Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, Trachtenberg J, Naglie G (2003) Patient and community preferences for outcomes in prostate cancer: Implications for clinical policy. Med Care 41: 153-164
14. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH (1998) The UCLA prostate cancer index: Development, reliability, and validity of a health-related quality of life measure. Med Care 36: 1002-1012 (Pubitemid 128456439)
15. Louviere J, Street D, Burgess L (2003) A 20+ years retrospective on choice experiments. In: , Wind Y, Green PE (eds), Marketing Research and Modeling: Progress and Prospects pp 201-214. Kluwer: New York
16. Louviere JJ, Hensher DA, Swait JD (2000) Stated choice methods: Analysis and applications. Cambridge University Press: Cambridge
17. Lubeck DP, Grossfeld GD, Carroll PR (2002) A review of measurement of patient preferences for treatment outcomes after prostate cancer. Urology 60: 72-77; discussion 77-8
18. McFadden D, Train K (2000) Mixed MNL models for discrete response. J Appl Econometrics 15: 447-470
19. Mols F, Korfage IJ, Vingerhoets AJ, Kil PJ, Coebergh JW, Essink-Bot ML, van de Poll-Franse LV (2009) Bowel, urinary, and sexual problems among long-term prostate cancer survivors: A population-based study. Int J Radiat Oncol Biol Phys 73: 30-38
20. National Comprehensive Cancer Network (2004) Prostate cancer. NCCN clinical practice guidelines in oncology. J Natl Compr Can Netw 2: 224-248
21. National Health and Medical Research Council (NHMRC) (2003) Clinical practice guidelines: Evidence-based information and recommendations for the management of localised prostate cancer. National Health and Medical Research Council: Canberra
22. Parker WR, Montgomery JS, Wood DP, Parker WR, Montgomery JS (2009) Quality of life outcomes following treatment for localized prostate cancer: Is there a clear winner? Curr Opin Urol 19: 303-308
23. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC, Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst 96: 1358-1367 (Pubitemid 39406169)
24. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC (2000) Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92: 1582-1592
25. Reeve BB, Potosky AL, Willis GB (2006) Should function and bother be measured and reported separately for prostate cancer quality-of-life domains? Urology 68: 599-603
26. Ryan M (2004) Discrete choice experiments in health care. BMJ 328: 360-361 (Pubitemid 38241179)
27. Saigal CS, Gornbein J, Nease R, Litwin MS (2001) Predictors of utilities for health states in early stage prostate cancer. J Urol 166: 942-946 (Pubitemid 32750989)
28. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT, Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostatecancer survivors. N Engl J Med 358: 1250-1261 (Pubitemid 351439226)
29. Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M (2004) Patients' preferences for the management of non-metastatic prostate cancer: Discrete choice experiment. BMJ 328: 382
30. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R (1991) Sex or survival: Trade-offs between quality and quantity of life. J Clin Oncol 9: 328-334
31. Smith DP, King MT, Egger S, Berry M, Stricker P, Cozzi P, Ward J, O'Connell DL, Armstrong BK (2009) Quality of life three years after diagnosis of localised prostate cancer: Population based cohort study. Br Med J 339: B4817
32. Smith DS, Krygiel J, Nease Jr RF, Sumner II W, Catalona WJ (2002) Patient preferences for outcomes associated with surgical management of prostate cancer. J Urol 167: 2117-2122 (Pubitemid 34309678)
33. Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ (2007) Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer 110: 2210-2217 (Pubitemid 350100742)
34. Stalmeier PF, van Tol-Geerdink JJ, van Lin EN, Schimmel E, Huizenga H, van Daal WA, Leer JW (2007) Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy. J Clin Oncol 25: 3096-3100 (Pubitemid 47218057)
35. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM (2005) Utilities for prostate cancer health states in men aged 60 and older. Med Care 43: 347-355 (Pubitemid 40515624)
36. Street DJ, Burgess L, Louviere JJ (2005) Quick and easy choice sets: Constructing optimal and nearly optimal stated choice experiments. Int J Res Marketing 22: 459-470 (Pubitemid 43045893)
37. Swait J, Louviere J (1993) The role of the scale parameter in the estimation and comparison of multinational logit models. J Marketing Res 30: 305-314
38. Thewes B, Meiser B, Duric V, Stockler MR, Taylor A, Stuart-Harris R, Links M, Wilcken N, McLachlan SA, Phillips KA, Beith J, Boyle F, Friedlander ML (2005) What survival benefits do premenopausal early breast cancer patients need to make endocrine therapy worthwhile? Lancet Oncol 6: 581-588 (Pubitemid 41051936)
39. Train K (2003) Discrete choice methods with simulation. Cambridge University Press: New York
40. van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, Schimmel EC, Huizenga H, van Daal WA, Leer JW (2006a) Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol 24: 4581-4586 (Pubitemid 46630955)
41. van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, Schimmel EC, Huizenga H, van Daal WA, Leer JW, van Tol-Geerdink JJ, Stalmeier PFM, van Lin ENJT, Schimmel EC, Huizenga H, van Daal WAJ, Leer J-W (2006b) Do prostate cancer patients want to choose their own radiation treatment? Int J Radiat Oncol Biol Phys 66: 1105-1111 (Pubitemid 44633523)
42. Wilke DR, Krahn M, Tomlinson G, Bezjak A, Rutledge R, Warde P, Wilke DR, Krahn M, Tomlinson G, Bezjak A, Rutledge R, Warde P (2010) Sex or survival: Short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy. Cancer 116: 1909-1917
43. Wilt T, Shamliyan T, Taylor B, MacDonald R, Tacklind J, Rutks I, Koeneman K, Cho C-S, RL K (2008) Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer Comparative Effectiveness Review No. 13. Available at: Www.effectivehealthcare.ahrq.gov/ reports/final.cfm. Agency for Healthcare Research and Quality: Rockville
44. Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW (2006) Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 106: 1865-1874 (Pubitemid 43673200)